Specific, highly sensitive and simple spectrofluorimetric method for quantification of daclatasvir in HCV human plasma patients and in tablets dosage form

Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma

(2017) Giulio Nannetti et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Development and validation of sensitive and rapid UPLC–MS/MS method for quantitative determination of daclatasvir in human plasma: Application to a bioequivalence study

(2016) Mamdouh R. Rezk et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

A UHPLC–MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma

(2016) Alessandra Ariaudo et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma

(2015) Hao Jiang et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

A validated LC–MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma

(2014) Long Yuan et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.

(2013) Marc Bifano et al.   ANTIVIRAL THERAPY